Elsevier

Bone

Volume 38, Issue 5, May 2006, Pages 617-627
Bone

Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite

https://doi.org/10.1016/j.bone.2005.05.003Get rights and content

Abstract

Bisphosphonates are now the most widely used drugs for diseases associated with increased bone resorption, such as osteoporosis. Although bisphosphonates act directly on osteoclasts, and interfere with specific biochemical processes such as protein prenylation, their ability to adsorb to bone mineral also contributes to their potency and duration of action.

The aim of the present study was to compare the binding affinities for hydroxyapatite (HAP) of 6 bisphosphonates currently used clinically and to determine the effects of these bisphosphonates on other mineral surface properties including zeta potential and interfacial tension.

Affinity constants (KL) for the adsorption of bisphosphonates were calculated from kinetic studies on HAP crystal growth using a constant composition method at 37°C and at physiological ionic strength (0.15 M). Under conditions likely to simulate bisphosphonate binding onto bone, there were significant differences in KL among the bisphosphonates for HAP growth (pH 7.4) with a rank order of zoledronate > alendronate > ibandronate > risedronate > etidronate > clodronate. The measurements of zeta potential show that the crystal surface is modified by the adsorption of bisphosphonates in a manner best explained by molecular charges related to the protonation of their side-chain moieties, with risedronate showing substantial differences from alendronate, ibandronate, and zoledronate. The studies of the solid/liquid interfacial properties show additional differences among the bisphosphonates that may influence their mechanisms for binding and inhibiting crystal growth and dissolution. The observed differences in kinetic binding affinities, HAP zeta potentials, and interfacial tension are likely to contribute to the biological properties of the various bisphosphonates. In particular, these binding properties may contribute to differences in uptake and persistence in bone and the reversibility of effects. These properties, therefore, have potential clinical implications that may be important in understanding differences among potent bisphosphonates, such as the apparently more prolonged duration of action of alendronate and zoledronate compared with the more readily reversible effects of etidronate and risedronate.

Introduction

Bisphosphonates are now the most widely used drugs for treating diseases associated with increased bone resorption, such as osteoporosis. Following the demonstration that inorganic pyrophosphate was a naturally occurring modulator of bone metabolism, the bisphosphonates, which are metabolically stable analogs of pyrophosphate, were studied as inhibitors of calcification and resorption for the treatment of bone disorders [1], [2], [3]. The earliest studies showed that bisphosphonates could bind to hydroxyapatite (HAP) crystals, and inhibit crystal growth and dissolution similar to pyrophosphate [4], [5]. The ability of bisphosphonates to inhibit bone resorption was initially ascribed to these direct inhibitory effects on mineral dissolution. However, with the development and study of increasingly potent bisphosphonates, it became clear that these physicochemical effects on bone mineral did not completely explain the inhibition of bone resorption, and cellular effects were likely to be involved [6], [7], [8]. It is now known that bisphosphonates also act directly on osteoclasts and interfere with specific intracellular biochemical processes such as isoprenoid biosynthesis and subsequent protein prenylation to inhibit cell activity [9], [10].

The high binding affinities of bisphosphonates for bone may affect many important biological properties of these compounds including uptake and retention on the skeleton, diffusion of the drug within bone, release of adsorbed drug from bone, potential recycling of the desorbed drug back onto bone surfaces, and effects on mineral dynamics and cellular function within bone. The strong binding of bisphosphonates to bone mineral together with the ability to be linked to a gamma-emitting technetium isotope [11] was the basis for the use of bisphosphonates as bone-scanning agents to detect metastases and other bone lesions. Many studies have shown that bisphosphonates have prolonged or persistent effects, both in experimental animals and in humans, which is probably related to the rate and extent of chemical desorption and cell-mediated release from bone [12], [13], [14], [15], [16], [17], [18].

Chemically, the bisphosphonates of medical interest are all characterized by 2 phosphonate groups sharing a common carbon atom (P–C–P). This P–C–P backbone is responsible for the strong affinity for bone mineral and thus facilitates the potent inhibitory effects on bone metabolism in vitro and in vivo. Both phosphonate groups are required, as modifications to one or both reduce affinity for bone mineral. It has been well established that R1 substituents (Table 1) with additional capability to co-ordinate to calcium, such as a hydroxyl (OH) or amino (NH2), can display enhanced chemisorption to mineral, presumably via tridentate binding to calcium [4].

Varying the R2 substituents can result in differences in antiresorptive potency of several orders of magnitude. Many bisphosphonates with an R2 side chain containing a basic primary nitrogen atom in an alkyl chain (e.g., pamidronate and alendronate) are more potent antiresorptive agents than either etidronate or clodronate, whereas compounds with more highly substituted nitrogen moieties in R2 (e.g., ibandronate) can display further increases in antiresorptive potency. The most potent antiresorptive bisphosphonates include those containing a nitrogen atom within a heterocyclic ring (e.g., risedronate and zoledronate). These enhancements in antiresorptive potency resulting from differences in the R2 groups appear to be linked to the biochemical activities of these drugs, particularly inhibition of the farnesyl diphosphate synthase enzyme within the mevalonic acid pathway in osteoclasts [19], [20], [21].

Although earlier studies showed differences in mineral binding among bisphosphonates such as etidronate and clodronate in which R1 was varied, the effects on mineral binding of varying R2 has not been systematically studied with many nitrogen-containing bisphosphonates. In a previous study, differences were found in the HAP adsorption isotherms at high equilibrium concentrations, even among bisphosphonates with the same R1 (OH) [20], [22]. The method used, however, did not allow for calculation of binding affinities.

In this present study, using an HAP crystal growth method, we measured the kinetic binding affinities of 6 bisphosphonates in current clinical use at concentrations more similar to in vivo conditions. We have also studied the effects of these bisphosphonates on other HAP surface properties that are likely to influence the mineral binding of bisphosphonates in vivo, including zeta potential and interfacial tension.

Section snippets

Materials

Six bisphosphonates (clodronate, etidronate, risedronate, ibandronate, alendronate, and zoledronate) were used in this study; their chemical names and structures are listed in Table 1. Clodronate has an R1 substituent of –Cl and the other bisphosphonates tested have –OH as the R1 substituent. All 6 compounds were synthesized and characterized in the Procter & Gamble Pharmaceuticals laboratories utilizing previously published methods [19]. HAP, prepared as described previously, was characterized

HAP growth

All 6 bisphosphonates studied produced concentration-dependent inhibition of HAP crystal growth (Table 2, Fig. 1, [2], Fig. 2). The rank order of inhibitory potency at these concentrations was zoledronate (most potent) ∼ alendronate > ibandronate ∼ risedronate > etidronate > clodronate (least potent). Fig. 1 shows representative plots of titrant volume versus HAP growth over time for risedronate and alendronate. The initial non-linear portion of the titrant curves represents expected titrant

Discussion

The results of this study show that even bisphosphonates that share a common P–C–P structure, with OH at R1, can have significantly different kinetic binding affinities for HAP with a rank order of highest to lowest for the bisphosphonates studied of zoledronate > alendronate > ibandronate = risedronate > etidronate. These differences must be attributed to differences in the R2 side chain. This study also showed that the nature of the R2 side chain influences other surface properties, including

Acknowledgments

We are grateful to Elaine B. Taylor for her assistance in the preparation and editing of the manuscript. We thank the National Institutes of Health (NIDCR) for a grant (DE03223) in partial support of this work.

References (75)

  • H. Fleisch et al.

    Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo

    Science

    (1969)
  • H. Fleisch

    Bisphosphonates in bone disease

    From the laboratory to the patient

    (2000)
  • H. Fleisch et al.

    Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis

    Nature

    (1966)
  • R.G. Russell et al.

    The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats

    Calcif. Tissue Res.

    (1970)
  • H.A. Fleisch et al.

    The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo

    Eur. J. Clin. Invest.

    (1970)
  • Benedict J.J., The physical chemistry of the diphosphonates—Its relationship to their medical activity. In: Donath A.,...
  • R.J. Sunberg et al.

    Designing drugs for stronger bones

    Chemtech

    (1991)
  • R. Schenk et al.

    Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats

    Calcif. Tissue Res.

    (1973)
  • M.J. Rogers

    New insights into the molecular mechanisms of action of bisphosphonates

    Curr. Pharm. Des.

    (2003)
  • R.G.G. Russell et al.

    Bisphosphonates: from the laboratory to the clinic and back again

    Bone

    (1999)
  • I. Fogelman et al.

    The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone diseases

    J. Nucl. Med.

    (1978)
  • S.B. Hornby et al.

    Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats

    Calcif. Tissue Int.

    (2003)
  • M. Glatt et al.

    Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid

    Osteoporos Int.

    (2004)
  • I.R. Reid et al.

    Intravenous zoledronic acid in postmenopausal women with low bone mineral density

    N. Engl. J. Med.

    (2002)
  • R.P. Tonino et al.

    Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women

    J. Clin. Endocrinol. Metab.

    (2000)
  • J.L. Stock et al.

    Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women

    Am. J. Med.

    (1997)
  • S.A. Khan et al.

    Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis

    J. Bone Miner. Res.

    (1997)
  • H.G. Bone et al.

    Ten years' experience with alendronate for osteoporosis in postmenopausal women

    N. Engl. J. Med.

    (2004)
  • F.H. Ebetino et al.

    Bisphosphonate antiresorptive structure–activity relationships

  • F.H. Ebetino et al.

    Mechanisms of action of etidronate and other bisphosphonates

    Rev. Contemp. Pharmacother.

    (1998)
  • J.E. Dunford et al.

    Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates

    J. Pharmacol. Exp. Ther.

    (2001)
  • A. Ebrahimpour et al.

    Bisphosphonate therapy in acute and chronic bone boss: physical chemical considerations in bisphosphonate-related therapies

  • J. Arends et al.

    Preparation of pure hydroxyapatite single crystals by hydrothermal recrystallization

    J. Cryst. Growth

    (1979)
  • P. Koutsoukos et al.

    Crystallization of calcium phosphates. A constant composition study

    J. Am. Chem. Soc.

    (1980)
  • B.R. Ware

    Electrophoretic light scattering

    Adv. Colloid Interface Sci.

    (1974)
  • R.J. Hunter

    Zeta potential in colloid science

    (1981)
  • I. Traube et al.

    Solubility and surface tension

    Ber

    (1927)
  • V.K. Semenchenko

    Solubility and surface tension

    Uspekhi Khimii

    (1934)
  • E. Bagda

    The relation between surface tension and the solubility parameter in liquids

    Farbe Lack

    (1978)
  • C.J. van Oss et al.

    Determination of contact angles and pore sizes of porous media by column and thin layer wicking

    J. Adhes. Sci. Technol.

    (1992)
  • E.W. Washburn

    Dynamics of capillary flow

    Phys. Rev.

    (1921)
  • C.J. van Oss

    Interfacial forces in aqueous media

    (1994)
  • P. Garnier et al.

    Dissolution kinetics of synthetic hydroxyapatite and human enamel crystals

    J. Biol. Buccale

    (1976)
  • J. Christoffersen et al.

    The kinetics of dissolution of calcium hydroxyapatite in water at constant pH

    J. Cryst. Growth

    (1978)
  • W.C. Chen et al.

    The kinetics of dissolution of tooth enamel—A constant composition study

    J. Dent. Res.

    (1986)
  • E.P. Paschalis et al.

    Dual constant composition kinetics characterization of apatitic surfaces

    J. Biomed. Mater. Res.

    (1994)
  • R. Tang et al.

    Constant composition dissolution of mixed phases: II. Selective dissolution of calcium phosphates

    J. Colloid. Interface Sci.

    (2003)
  • Cited by (0)

    View full text